Consider the alternatives for CNS with QCTR - CNS Orphan Diseases

PRLog (Press Release) - Mar. 1, 2013 - GBI Research (2012) stated that the CNS orphan disease market's Compound Annual Growth Rate (CAGR) is forcasted to increase by 17.6%, accelerating the industry's worth up to $2.1 billion in 2017. Novel Agents such as AMR101 and ACR16 will be introduced to deliver treatment options and to improve the Huntington's Disease division, which will provide valuable insights into the CNS orphan disease therapeutics market. However challenges do arise during trials, as not only does the development stages take longer it is also more costly in the later stages during trials. This problem can be illustrated in the phase III trials in Alzheimer's disease. Diseases such as Progressive Supranuclear Palsy (PSP), Fronto-Temporal Dementia (FTD) or Huntington's disease can be initial substitutes for the likes of Alzheimer's disease or Parkinson's disease in which to test the effectiveness of a drug.

This timely masterclass will assess the latest challenges and potential advantages of developing drugs in CNS Orphan diseases, compared to larger CNS indications and also looks at the support that is available to drug developers in orphan diseases. Furthermore, case studies of drug companies who have followed this route will be reviewed and lessons learnt will be drawn from them to assist you with developing your own strategies.~

Delegates attending will benefit from:
• Discover alternative routes for drug development in CNS disorders
• Minimise the risks associated with developing drugs in larger CNS conditions
• Learn from past trials and from the successes small-medium sized pharma and biotechs have had in developing drugs in orphan CNS indications
• Evaluate the support structures available to those undertaking clinical trials in
• Orphan disease indications
• Identify the challenges involved in developing compounds in Orphan CNS disease indications

---END---

*notes to editors

About the Masterclass leader:
Susan McGoldrick is the CEO and founder of QCTR and has worked in the Pharmaceutical industry in executive management roles for 15 years. Initially starting out with a medium-sized pharma company, Susan then moved onto a small biotech company specializing in CNS drug development process including hands-on experience of regulatory interactions with the FDA and EMA and agreeing the clinical requirements for obtaining marketing approval.

About QCTR:
QCTR is an international; niche CRO specialising in neurology, psychiatry and orphan indications. They are recognized internationally as experts conducting proof of concept and pivotal phase II and III trials in CNS. Through their unique approach, QCTR can deliver patient recruitment to their clients in this notoriously difficult field. QCTR will get you to Last Patient In in as timely a manner as First Patient In.

To view the conference programme and full speaker line-up, visit http://www.smi-online.co.uk/orphan-cns12.asp

Alternatively contact Jonathan Collins on +44 (0) 20 7827 6734 or jcollins@smi-online.co.uk

Photo:
http://www.prlog.org/12089191/1